title: Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling.
abstract: BACKGROUND
  Changes in matrix metalloproteinase (MMP) and tissue inhibitors of MMPs (TIMPs) contribute to left ventricular (LV) remodeling after myocardial infarction (MI). We tested the hypothesis that a specific plasma MMP/TIMP profile would emerge after MI and be associated with the degree of LV dilation.
  
  
  RESULTS
  LV end-diastolic volume and MMP/TIMP plasma profiles were determined in 53 age-matched control subjects and 32 post-MI patients from day 1 through 180 after MI. LV end-diastolic volume increased by > 38% at day 90 after MI (P < 0.05). MMP-9 increased by > 150% from control at day 1 after MI (P < 0.05) and remained elevated. MMP-8 rose to > 120% at day 3 after MI (P < 0.05) and fell to control values by day 5. TIMP-1 increased by > 60% from control at day 1 after MI (P < 0.05), whereas TIMP-2 increased only at later time points. Cardiac-specific TIMP-4 fell by 40% at day 5 after MI and remained reduced. A persistent or elevated MMP-9 at day 5 was accompanied by a 3-fold end-diastolic volume increase at day 28 (P < 0.05).
  
  
  CONCLUSIONS
  A specific temporal pattern of MMP/TIMPs occurred in post-MI patients that included an early and robust rise in MMP-9 and MMP-8 and a uniform fall in TIMP-4. These findings suggest that a specific MMP/TIMP plasma profile occurs after MI and holds both prognostic and diagnostic significance.
authors.affiliation: Division of Cardiology, Department of Medicine, Medical University of South Carolina, Charleston, SC 29425, USA.
authors.forename: Carson S
authors.initials: CS
authors.lastname: Webb
authors.forename: David D
authors.initials: DD
authors.lastname: Bonnema
authors.forename: S Hinan
authors.initials: SH
authors.lastname: Ahmed
authors.forename: Amy H
authors.initials: AH
authors.lastname: Leonardi
authors.forename: Catherine D
authors.initials: CD
authors.lastname: McClure
authors.forename: Leslie L
authors.initials: LL
authors.lastname: Clark
authors.forename: Robert E
authors.initials: RE
authors.lastname: Stroud
authors.forename: William C
authors.initials: WC
authors.lastname: Corn
authors.forename: Laura
authors.initials: L
authors.lastname: Finklea
authors.forename: Michael R
authors.initials: MR
authors.lastname: Zile
authors.forename: Francis G
authors.initials: FG
authors.lastname: Spinale
mesh_terms: D015415:Biomarkers / Q000097:blood; D004562:Electrocardiography; D005260:Female; D018093:Gelatinases / Q000097:blood; D006801:Humans; D008297:Male; D020782:Matrix Metalloproteinases / Q000097:blood*; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood / Q000188:drug therapy / Q000201:enzymology*; D012016:Reference Values; D015912:Thrombolytic Therapy; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000097:blood; D019716:Tissue Inhibitor of Metalloproteinase-2 / Q000097:blood; D020257:Ventricular Remodeling / Q000502:physiology
chemical_list: D015415:Biomarkers; D019715:Tissue Inhibitor of Metalloproteinase-1; D019716:Tissue Inhibitor of Metalloproteinase-2; D018093:Gelatinases; D020782:Matrix Metalloproteinases